Table 2.
Clinical trials of bortezomib in triplet-drug combination regimens
| Study | Phase | Regimen | n/N | CR/nCR | ORR |
|---|---|---|---|---|---|
| Reece et al23 | I/II | VCP | 37/37 | 27% | 68% |
| Kropff et al24 | II | VCD | 50/54 | 16% CR | 82% |
| Hajek et al25 | II | 39/40 | – | 51% | |
| Lee et al26 | II | PAD→TD | 30/39 | 70% | 90% |
| Palumbo et al27 | PAD | 64/64 | 25% | 67% | |
| Richardson et al28 | II | VRD | 62/24 | 21% | 84% (≥MR) |
| Poensich et al29 | II | VBP | 46/46 | 15% | 61% |
Abbreviations: n/N, number of evaluable patients/total number of enrolled patients; VCP, bortezomib, cyclophosphamide, prednisone; VCD, bortezomib, cyclophosphamide, dex; PAD, bortezomib, adriamycin, dex; TD, thalidomide, dex; VRD: bortezomib, lenalidomide, dex; VBP, bortezomib, bendamustine, prednisone.